The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Review of the current status of KRAS mutation testing in France in 2011: The Flash-KRAS study.
Pascal Artru
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Michel Ducreux
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Astrid Lièvre
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Michel Guiu
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Jean-Louis Merlin
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Jean-Christophe Sabourin
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Jérôme Viguier
Consultant or Advisory Role - Merck Serono
Anne Bastie
Employment or Leadership Position - Merck Serono
Audrey Seronde
Employment or Leadership Position - Merck Serono
Pierre Laurent-Puig
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono